ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health
Phase 3positiveFoundayoPositive
AI Analysis
Summary
Lilly's Foundayo (orforglipron) met primary endpoints in the ACHIEVE-4 Phase 3 trial, demonstrating non-inferiority to insulin glargine with significant cardiovascular benefits including 16-23% lower MACE risk and 57% lower all-cause mortality risk.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Met primary objective of non-inferiority vs. insulin glargine with 16% lower risk of MACE-4 events and 23% lower risk of MACE-3 events. Pre-planned analysis showed 57% lower risk of all-cause death for Foundayo vs. insulin glargine.
Importance:8/10
Sentiment:
0.85
Phase 3 datacardiovascular safetyMACE reductionmortality benefitdiabetes
Related Companies
Read the original article
Published by PR Newswire Pharma on April 16, 2026 10:45 AM